Design Therapeutics Ends 2025 with $219.8M Cash, DT-818 Dosing in H1 2026
Design Therapeutics reported a $16.0M fourth-quarter net loss and $69.8M annual deficit in 2025 while incurring $59.1M in R&D and $20.3M in G&A expenses. As of December 31, 2025, cash and securities totaled $219.8M, funding operations into 2029, and DT-818 DM1 dosing starts H1 2026.
1. Financial Results
Design Therapeutics posted a $16.0M net loss in the fourth quarter and a $69.8M net loss for full-year 2025, driven by $59.1M in R&D spending and $20.3M in G&A expenses.
2. Cash Position and Runway
Cash, cash equivalents and investment securities amounted to $219.8M at year-end 2025, providing funding for planned operations into 2029 without additional financing.
3. Clinical Pipeline Progress
The RESTORE-FA Phase 1/2 trial of DT-216P2 continues dosing with a frataxin level update expected in H2 2026; the DT-168 Phase 2 FECD biomarker trial is ongoing with data due in H2 2026; and DT-818 Phase 1 multiple-ascending-dose trial in DM1 will begin patient dosing in H1 2026, with results expected in 2027.